TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10629624
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg i.v. q 4 weeks
Study: 1933707
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (0.5 mg in 2.5 mL)
Study: 1933707
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (2.5 mL)
Study: 7141686
Drug: Live influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live influenza A/Victoria/75 (H3N2) recombinant virus vaccine with ts‐1[E] (38 degrees C shut‐off temperature)
Study: 7141686
Drug: Live influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live influenza A/Victoria/75 (H3N2) recombinant virus vaccine with ts‐1A2 (37 degrees C shut‐off temperature)
Study: 7141686
Drug: Live influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live influenza A/Victoria/75 (H3N2) recombinant virus vaccines with cold‐adapted A/Ann Arbor/6/60
Study: 7141686
Drug: Live influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live influenza A/Victoria/75 (H3N2) recombinant virus vaccines
Study: 7141686
Drug: Unvaccinated volunteers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unvaccinated volunteers with little or no serum antibody
Study: 29461654
Drug: Structured aerobic
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured aerobic and resistance exercise program performed twice per week, including 20 minutes of aerobic exercise, 20-25 minutes of resistance exercise, and 10 minutes of cool down.
Study: 28178072
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac + 1.2 mg atropine
Study: 28178072
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 1.2 mg atropine
Study: 28178072
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac + placebo
Study: 24392486
Drug: Multidirectional FRC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidirectional FRC groups (g to l)
Study: 21180658
Drug: Glucocorticoid administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucocorticoid administration
Study: 16791287
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maximum medical treatment)
Study: 3542942
Drug: Ciprofloxacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (100 mg bd for five days)
Study: 3542942
Drug: Trimethoprim (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (200 mg bd for five days)
Study: 12823643
Drug: B-vitamins (folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamins (folic acid 2 mg and vitamin B12 1 mg)
Study: 12823643
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins (vitamin E 500 mg and vitamin C 200 mg)
Study: 10910802
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of hydrocortisone
Study: 10910802
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of ovine CRH
Study: 8955969
Drug: Terbutaline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (5 mg in 2 ml normal saline)
Study: 22503786
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (4 ml)
Study: 8955969
Drug: Atropine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.01 mg.kg-1, iv)
Study: 3837132
Drug: Prostin 15-M
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostin 15-M (8.92 ml, 28h 30' for group A; 8.23 ml, 23h 23' for group B; 4.97 ml, 16h for group C)
Study: 28462869
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) given for 5 months in blended form (face-to-face and web-based sessions)
Study: 27507989
Drug: 5% curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% curcumin oral paste three times a day for four weeks
Study: 23322191
Drug: Epidural methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural methadone 2.5 mg with 40 mg lidocaine
Study: 23322191
Drug: Epidural methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural methadone 5 mg with 40 mg lidocaine
Study: 23322191
Drug: Epidural methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural methadone 7.5 mg with 40 mg lidocaine and 10 mg dexamethasone
Study: 22183840
Drug: Episodic acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Episodic acyclovir therapy
Study: 10719650
Drug: Intra-arterial thrombolytic
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial thrombolytic therapy
Study: 30853042
Drug: Sleep health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep health program (4 weekly group sessions)
Study: 29740768
Drug: Recommended dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dose of NPK (control)
Study: 26250435
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (iron sulphate, 200 mg daily for 8 weeks)
Study: 22990269
Drug: High-dose aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aerobic training (40 min/d; n = 73)
Study: 22990269
Drug: Low-dose aerobic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aerobic training (20 min/d; n = 71)
Study: 17439905
Drug: Fampridine-SR (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fampridine-SR (10 to 40 mg twice daily, increasing in 5 mg increments weekly)
Study: 15055251
Drug: Bedtime administration
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime administration of trandolapril
Study: 15055251
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of trandolapril
Study: 9695314
Drug: ipriflavone 600
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipriflavone 600 mg/day (OSTEN)
Study: 9695314
Drug: daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral administration of 2 g calcium lactate and 0.5 microgram alphacalcidol (Ca.D)
Study: 9695314
Drug: repeated 14‐week
Approvals — FDA: no, EMA: no, PMDA: no
Description: repeated 14‐week cycle of daily oral administration of 2 micrograms alphacalcidol for 2 weeks, 600 mg of ipriflavone for 4 weeks, and 2 g calcium lactate together with 0.5 microgram alphacalcidol for 8 weeks (ADFR)
Study: 7197963
Drug: Formulation 1
Normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 1 (standard formulation)
Study: 7197963
Drug: Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 2 (test formulation)
Study: 30653262
Drug: PSA screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA screening (cut-off of 4.0 ng/ml), 2-3 screening rounds offered
Study: 28143496
Drug: Advice and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice and paracetamol
Study: 20971822
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (40 mg/m(2)) and standard vincristine (2 mg) on day 1, followed by dexamethasone and a second cycle at day 28, reinforced by cyclophosphamide
Study: 20971822
Drug: Continuous-infusion doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion doxorubicin (12 mg/m(2)/day) and continuous-infusion vincristine (0.4 mg/day) on days 1-4
Study: 17082518
Drug: Oral presentation
Normalized name: Gas-X Prevention Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral presentation of information in the flow chart (Group D)
Study: 11358727
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily treatment of dithranol
Study: 11358727
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly treatment of dithranol
Study: 8362531
Drug: hGH (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH (8 IU) plus HPN (1.0-1.5 g protein/kg/day and 900 kcal/day)
Study: 18999171
Drug: Treatment results
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment results distributed via email to collaborating institutions, with blinded recipients not notified of the subject's treatment selection.
Study: 16043737
Drug: Low-dose parenteral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose parenteral insulin (human ultralente insulin at 0.25 units x kg(‐1) x day(‐1))
Study: 1684872
Drug: Diazepam (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.12 mg/kg)
Study: 1684872
Drug: Ondansetron (0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.24 mg/kg)
Study: 25623462
Drug: Microecologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microecologic treatment combined enteral nutrition
Study: 22827780
Drug: Soy nuts
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy nuts (35 g/d)
Study: 22827780
Drug: Textured soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Textured soy protein (TSP) (35 g/d)
Study: 19208678
Drug: PPV combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV combined with one IVB (1.5 mg/0.06 ml) injection 2 weeks prior to surgery (BEV/PPV group)
Study: 17205251
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% in 50 ml of saline 0.9% (Group B)
Study: 17205251
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% in 40 ml of saline 0.9% (Group C)
Study: 15140341
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg once daily for 10 days
Study: 9702472
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ANP (2.5 pmol kg‐1 min‐1)
Study: 9702472
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ANP (5.0 pmol kg‐1 min‐1)
Study: 7980309
Drug: Local ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local ablative therapy
Study: 7980309
Drug: Condom use
Normalized name: CONDOM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condom use after ablative therapy
Study: 2967742
Drug: Isradipine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (15 mg/day, 5 mg t.i.d.)
Study: 2967742
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg/day, 80 mg t.i.d.)
Study: 31709984
Drug: Stratified medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified medical therapy guided by invasive coronary function testing
Study: 25974723
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement containing whey (LNS/w)
Study: 25974723
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement containing soy (LNS/s)
Study: 25974723
Drug: No lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-based nutrient supplement (Control)
Study: 25974723
Drug: CYP2B6 516
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2B6 516 G>T polymorphism
Study: 16564934
Drug: AST-120 (Kremezin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (Kremezin) 0.9 g, 2.1 g, or 3.0 g, administered 3 times daily for 12 weeks
Study: 16564934
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered 3 times daily for 12 weeks
Study: 1536441
Drug: Intramuscular buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular buprenorphine (opioid group)
Study: 17387123
Drug: Home-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based medication review by a pharmacist
Study: 12528325
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum milk preparation (42 g per day for 2 days preoperatively)
Study: 2527760
Drug: Oral thymoxamine
Normalized name: thymoxamine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thymoxamine 40 mg
Study: 2527760
Drug: Oral thymoxamine
Normalized name: thymoxamine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thymoxamine 80 mg
Study: 202985
Drug: Viloxazine 200
Normalized name: viloxazine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine 200 mg daily for 3 weeks
Study: 202985
Drug: Viloxazine 300
Normalized name: viloxazine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine 300 mg daily for 3 weeks
Study: 31262551
Drug: Face-to-face treatment
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face treatment (FtF)
Study: 31262551
Drug: Chat-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chat-based treatment
Study: 28651927
Drug: Doxorubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin plus evofosfamide (300 mg/m2 intravenously for 30-60 min on days 1 and 8 of every 21-day cycle for up to six cycles)
Study: 28651927
Drug: Doxorubicin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin alone (75 mg/m2 via bolus injection or continuous intravenous infusion for 6-96 h on day 1 of every 21-day cycle for up to six cycles)
Study: 19344047
Drug: KADIAN q24h
Approvals — FDA: no, EMA: no, PMDA: no
Description: KADIAN q24h dosing
Study: 19344047
Drug: KADIAN q12h
Approvals — FDA: no, EMA: no, PMDA: no
Description: KADIAN q12h dosing
Study: 19344047
Drug: KADIAN q12h
Approvals — FDA: no, EMA: no, PMDA: no
Description: KADIAN q12h dosing after switch
Study: 11144399
Drug: Amoxicillin/CA 13.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/CA 13.3 mg/kg t.i.d.
Study: 9134599
Drug: BCG therapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG therapy (120 mg in 50 mL saline, 5 x 10^7 viable organisms), weekly for 6 weeks after TUR
Study: 31362537
Drug: MBB coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBB coaching (treatment)
Study: 21053789
Drug: Integrated dementia
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated dementia intervention (cognitive stimulation training, exercise, music, art, and horticultural therapy)
Study: 15480814
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/day (escalating to 10 mg after 1 month) and vitamin E 1,000 IU/day
Study: 12078939
Drug: Non-tapering prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-tapering prednisolone (40 mg/day for 8 days)
Study: 12078939
Drug: Tapering prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering prednisolone (40 mg tapering by 5 mg/day for 8 days)
Study: 9698776
Drug: Sublingual propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual propranolol (40 mg)
Study: 9698776
Drug: Peroral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral propranolol (40 mg)
Study: 7608665
Drug: Apomorphine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (mean dose 3.4 mg, range 0.8-6.0 mg)
Study: 30629187
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) initiated in HIV-infected adults
Study: 30934797
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g PGX granules (PGXG)
Study: 26306332
Drug: Florfenicol at
Normalized name: Florfenicol
DrugBank: Florfenicol (DB11413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Florfenicol at 10 mg/kg (medicated feed)
Study: 26306332
Drug: Unmedicated feed
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmedicated feed (0 mg/kg)
Study: 19295645
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g) + Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
Study: 19295645
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g) + Placebo
Study: 11208725
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide 50 microg
Study: 11208725
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide 500 microg
Study: 11208725
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide 50 microg bolus followed by continuous infusion of 50 microg/h
Study: 11208725
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide 250 microg/h continuous infusion
Study: 11208725
Drug: Repeated 50
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated 50 microg injections of octreotide after an initial bolus
Study: 11208725
Drug: Placebo bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus and continuous octreotide infusion (50 microg/h)
Study: 7929833
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion during fasting (n = 6)
Study: 7929833
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion during euglycemic insulin clamp (n = 8)
Study: 7929833
Drug: Control forearm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control forearm during euglycemic insulin clamp
Study: 7929833
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion in one forearm during euglycemic insulin clamp
Study: 3129445
Drug: Naloxone (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.08 mg/kg BW, iv)
Study: 30297240
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy regimens (folinic acid, fluorouracil, and oxaliplatin or fluorouracil, leucovorin, and irinotecan, with or without cetuximab)
Study: 16844625
Drug: Plasma levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma levels of TNF‐alpha rose more than 20 pg/mL during and after standard CPB in 13 patients (group 1)
Study: 16844625
Drug: Plasma levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma levels of TNF‐alpha were less than 20 pg/mL in the remaining 7 patients (group 2)
Study: 12727963
Drug: Low-dose GH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GH (Genotropin 0.4 mg/d) for 8 months
Study: 10969256
Drug: Botulinum-A toxin
Normalized name: Botulinum A neurotoxin
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum-A toxin (BTA) injection plus occupational therapy
Study: 2003499
Drug: Medication profile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication profile review by a clinical pharmacist
Study: 2003499
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication profile review)
Study: 26657482
Drug: Spray application
Normalized name: Inhalation Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray application of fluoride mouthwash (0.05% NaF; 226-ppm fluoride)
Study: 21128879
Drug: dalcetrapib 600
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dalcetrapib 600 mg/day
Study: 17389338
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m2/d for 5 days IV, repeated every 28 days)
Study: 17389338
Drug: Fludarabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine plus cyclophosphamide (FC) (fludarabine 30 mg/m2/d for 3 days IV plus cyclophosphamide 250 mg/m2/d for 3 days, repeated every 28 days)
Study: 16344188
Drug: Sutter implant
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutter implant replacement arthroplasty
Study: 16344188
Drug: Swanson implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swanson implant replacement arthroplasty
Study: 16540800
Drug: MMN (iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMN (iron 12.5 mg + folic acid 150 microg + zinc 5 mg)
Study: 16540800
Drug: FFA (iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFA (iron 12.5 mg + folic acid 150 microg)
Study: 8878221
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A (50,000 to 200,000 IU of retinyl palmitate, doses according to age; n = 89)
Study: 8878221
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A (for subgroup with significant hypoxemia)
Study: 1512341
Drug: Hydrochlorothiazide and
Normalized name: hydrochlorothiazide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide and amiloride (50 + 5 mg)
Study: 1512341
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (19 +/- 1 mg/24 h)
Study: 6421013
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg three times a day for 1 week
Study: 29966038
Drug: Roxadustat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (100 mg) under fed conditions
Study: 29966038
Drug: Roxadustat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (100 mg) under fasted conditions
Study: 29966038
Drug: Roxadustat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (100 mg) with SCA